UNSPSC 51314202: Flutropium

This classification denotes a mast cell stabilizer with the molecular formula C24H29FNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TA73FX29II, chemically known as [(1R,5R)-8-(2-fluoroethyl)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl]2-hydroxy-2,2-diphenylacetate but generally known as flutropium, which bears US NIH Compound Identifier 71962. European Medicines Agency schedules Flutropium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02242MIG.

UNSPSC 51314202 Flutropium is a Commodity-code medication used in respiratory therapy that state and local governments procure primarily through pharmacy benefit programs and direct-purchase agreements for health departments and community health facilities. Recent solicitations reveal that state and local buyers use this code to source generic pharmaceuticals and specialized medical products—including naloxone, drug deactivation systems, and OTC medications—through competitive bidding, cooperative purchasing alliances, and direct-to-manufacturer arrangements. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope of work spans annual supply contracts with quarterly or on-demand delivery to health facilities, compliance with cGMP and FDA requirements, and integration with authorized pharmaceutical wholesalers.

Geographic activity centers on Florida, Texas, Minnesota, and Oregon, with activity driven by state-level cooperative purchasing vehicles that aggregate demand across participating jurisdictions. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with contracts effective July 1, 2026. Contract terms typically run two years with renewal options, vendor pricing is weighted heavily on competitiveness (up to 75 percent of evaluation), and insurance requirements commonly include commercial general liability of $2 million to $5 million per occurrence.